Pharm - Antivirals Flashcards
Classes of antiviral medications
Nucleoside reverse transcriptase inhibitors (NRTIs)
Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
Integrase inhibitors
Protease inhibitors
Recommended initial ART regimens for HIV
Integrase inhibitor
(dolutegravir/abacavir/lamivudine)
Integrase inhibitor (Dolutegavir) + NRTI
(tenovir/emtricitabine)
Antiretroviral therapy for HIV is intended to be
polytherapy
Tenofovir (disoproxil fumerate/TDF or alafenamide/TAF) class
NRTI
Tenofovir adverse effects
Renal insufficiency, much improved with TAF
Special considerations for tenofovir
Use with emtricitabin for pre-exposure prophylaxis and post exposure prophylaxis
Name 2 combinations Tenofovir products
Emtricitabine + TDF (Truvada)
Emtricitabine + TAF (Descovy)
Emtricitabine (Emtriva) class
NRTI
Adverse effects of emtricitabine
Hyperpigmentation of palms
Skin discoloration
Zidovudine (Retrovir) class
NRTI
Adverse effects of Zidovudine
Bone marrow suppression, anemia
Special considerations for Zidovudine (Retrovir)
Caution with Epivir HBV
Renal dose adjustments
Efavirance (Sustiva) class
NNRTI
When is efavirance (sustiva) taken?
At bed time
Should efavirance (sustiva) be taken on a full or empty stomach
Empty stomach
Adverse effects of efavirance
CNS effects (drowsiness, lucid dreams, nightmares)
Rash
Elevated LFTs
Teratogenic
False positive cannabinoid test
Efavirance can be formulated with _______ and ________ (ATRIPLA)
Tenofovir DF, emtricitabine
Rilpivirine (Edurant) dosing consideration
Not for use in high viral loads
Rilpivirine drug interactions
Avoid use with PPIs
Issues with the protease inhibitor class
Drug interactions
Metabolic syndrome
Hepatotoxicity
GI intolerance
Osteopenia/osteoporosis
Atazanavir (Reyataz) class
Protease inhibitor
Special considerations for atazanavir
Avoid with PPIs
Adverse effects of Atazanavir
Indirect hyperbilirubinemia
Lack of effect on lipids
Darunavir (Prezista) class
Protease inhibitor
Special considerations with Darunavir
Caution with sulfa allergic patients
Adverse effects of Darunavir (Prezista)
Rash (7%)
Hepatotoxicity
Dolutegravir (Tivicay) class
Integrase inhibitor
Special considerations for Dolutegravir
Increased creatine kinase
Weight gain (particularly in women and AA/Hispanic populations)
Bictegravir class
Integrase inhibitor (newest)
Special considerations for Bictegravir
Drug interactions
Increase CK (4%)
Recommended initial treatment for HIV
Integrase inhibitor + NRTI